The lack of sufficient clinical benefits of anti-VEGF drugs in human cancer patients has raised several unresolved issues including: the mode of action, selection of responsive patient populations, treatment timeline and drug resistance mechanisms. The gene discussed is VEGFA; the disease is cancer.